CCM Biosciences Announces Presentation of Data on its First-In-Class AML Drug Program at ASCO 2025
By Business Wire Published on May 21, 2025, 14:15 IST
Mount Laurel, N.J., United States:
CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its next-generation FLT3 inhibitor drug program for acute myeloid leukemia (AML) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago.
Acute Myeloid Leukemia (AML) is the most severe form of leukemia with few treatment options, and a malignancy frequently driven by mutations in the FMS-like tyrosine kinase 3 (FLT3) gene. The FLT3 internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations, particularly D835 and F691, appear in approximately 30% of AML patients, often leading to poor prognosis and resistance to existing therapies. Gilteritinib (Xospata®; Astellas Pharma, peak annual sales projection: $1.5 billion) and Quizartinib (Vanflyta®; Daiichi Sankyo) are two FDA-approved FLT3 inhibitors, with the former approved only for relapsed/refractory AML and the latter approved only for newly diagnosed AML. Quizartinib does not target TKD resistance mutations, whereas Gilteritinib's efficacy on FLT3-ITD-D835 mutations is limited and it is not effective against the FLT3-ITD-F691 gatekeeper mutation, both of which are very common. Crenolanib (AROG/Pfizer) is an FLT3 inhibitor whose NDA submitted to the FDA does not address the indications above, whose NDA was previously rejected by the FDA, and which binds to FLT3 mutants less tightly than Gilteritinib. Consequently, there is a critical need for next-generation FLT3 inhibitors that can address all of these mutations.
At ASCO 2025, CCM Biosciences' presentation 'Novel, Potent and Selective Inhibitors Targeting FLT3 for AML Therapy' in the Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant session (Abstract #: 6542, https://www.asco.org/abstracts-presentations/ABSTRACT502974) will report novel FLT3 inhibitors have been identified that can both target FLT3-ITD and potentially overcome mutational resistance to FDA-approved FLT3 inhibitors. These agents are significantly more effective than Gilteritinib and have significant potential clinical applications.
CCM Biosciences' novel, orally bioavailable FLT3 inhibitors (CCM-405 and CCM-445) are the first drug candidates to overcome both FLT3-ITD juxtamembrane domain and tyrosine kinase domain (TKD) mutational drug resistance (including D835Y, F691L), significantly outperforming the aforementioned current-generation inhibitors both in the absence and presence of resistance mutations. Other reported investigational drug candidates capable of addressing FLT3-ITD resistance mutations either have poor pharmacokinetics, significant off-target binding, or both.
CCM Biosciences is advancing clinical candidates from its FLT3 inhibitor program to investigational new drug (IND) filing this year for entry into clinical trials for both newly diagnosed FLT3-positive AML and relapsed/refractory FLT3-positive AML. Multiple failures in AML clinical trials from competitors in 2024 present an attractive landscape for clinical trials of these drug candidates.
The company is actively partnering with biotechnology and pharmaceutical companies for co-development rights in selected countries. CCM Biosciences, a sister company of the global chemical and pharmaceutical services company PMC Group, Inc., is also a Featured Exhibitor at ASCO 2025 — https://asco25.myexpoonline.com/co/ccm-biosciences — and will be showcasing both its drug programs and the state-of-the-art platforms used to discover and develop them.
About CCM Biosciences
CCM Biosciences is a diversified biotechnology company dedicated to discovering and developing novel drugs, including small molecules, gene therapies, biologics, and nanomedicines within multiple corporate subsidiaries. CCM's patented drug discovery platforms were developed at Chakrabarti Advanced Technology, a privately funded R&D institute founded in 2010 with scientists in the US, France and India and with publications in leading scientific journals including PNAS, Nucleic Acids Research, Physical Review, American Chemical Society journals, Biophysical Society journals, and Nature Publishing Group journals. These platforms are complemented by the contract research, development, and manufacturing organizations (CRDMO) at PMC Group, the sister company of CCM Biosciences and a global chemical and pharmaceutical company with ~$1 billion in annual revenue.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250520081225/en/
Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same.
Business Wire is an American company that disseminates full-text press releases from thousands of companies and organizations worldwide to news media, financial markets, disclosure systems, investors, information web sites, databases, bloggers, social networks and other audiences.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNN
an hour ago
- CNN
Salmonella outbreak linked to eggs sickens dozens of people across 7 states
More than 70 people across seven states have been sickened due to a salmonella outbreak linked to eggs recalled by a California-based egg distributor, according to the US Centers for Disease Control and Prevention. On Friday, the August Egg Company recalled 1.7 million dozen brown cage-free and brown certified organic eggs, sold under multiple brand names, that have the 'potential to be contaminated,' according to a recall notice from the US Food and Drug Administration. Of the 79 people sickened, 21 people have been hospitalized and no deaths have been reported, the CDC said. The eggs were sold to restaurants and retailers in Arizona, California, Illinois, Indiana, Nebraska, New Mexico, Nevada, Washington and Wyoming, according to the CDC. They were distributed at retail locations including Walmart, Save Mart, FoodMaxx, Lucky, Smart & Final, Safeway, Raleys, Food 4 Less and Ralphs. Salmonella can 'cause serious and sometimes fatal infections in young children, frail or elderly people, and others with weakened immune systems,' according to the FDA. Salmonella can also cause fever, diarrhea, nausea, vomiting and abdominal pain in healthy people who get infected. 'August Egg Company is not selling fresh shell eggs at this time. Our firm has voluntarily been diverting eggs to an egg-breaking plant for over 30 days, which pasteurizes the eggs and kills any potential foodborne pathogens,' the company said in a statement provided to the FDA. 'It is important to know that when our processing plant identified this concern, we immediately began diverting all eggs from the plant to an egg-breaking facility, which pasteurizes the eggs and kills any pathogens.' The company also said its internal food safety team is 'conducting its own stringent review' to identify future preventative measures. 'We are committed to addressing this matter fully and to implementing all necessary corrective actions to ensure this does not happen again,' the company said. The CDC recommends that anyone who has the recalled eggs in their home or business throw them out or return them to the store where they were purchased.
Yahoo
an hour ago
- Yahoo
At Least 1.7 Million Eggs Have Been Recalled Across the U.S. — Here Are the States Affected
At least 1.7 million eggs have been recalled in the U.S. over potential salmonella contamination, according to the U.S. Food and Drug Administration (FDA) The recall impacts shoppers in California, Washington, Nevada, Arizona, Wyoming, New Mexico, Nebraska, Indiana and Illinois The FDA said 79 cases have been reported so far, and 21 people have since been hospitalizedThe U.S. Food and Drug Administration (FDA) has issued a recall of at least 1.7 million eggs. According to a news release from the organization, "brown cage-free and brown certified organic eggs" from the August Egg Company had the "potential to be contaminated" with salmonella, which can cause weakened immune systems and sometimes fatal infections in young or elderly people. The affected eggs were distributed to Walmart locations in nine states — California, Washington, Nevada, Arizona, Wyoming, New Mexico, Nebraska, Indiana and Illinois — between Feb. 3 and May 6 and featured sell-by dates ranging from March 4 to June 19, the FDA said. The eggs were also distributed to locations such as Save Mart, FoodMaxx, Lucky, Smart & Final, Safeway, Raleys, Food 4 Less and Ralphs in California and Nevada between Feb. 3 and May 15 with sell-by dates ranging from March 4 to June 4, the organization added. The FDA has shared a full list of the over-20 egg products that are being recalled, including Clover, Sunnyside and Raley's eggs. The foot items were sold in fiber or plastic cartons with codes P-6562 or CA5330 printed on one side, the organization said. The Centers for Disease Control and Prevention (CDC) is currently investigating what it's calling the "multi-state outbreak of salmonella infections" connected to the eggs. A total of 79 cases have been reported in seven states, while 21 people have been hospitalized, per the FDA. "We believe it is appropriate out of an abundance of caution to conduct this voluntary recall, as consumers may still have these eggs in their homes," the August Egg Company said in a statement shared with the FDA. 'It is important to know that when our processing plant identified this concern, we immediately began diverting all eggs from the plant to an egg-breaking facility, which pasteurizes the eggs and kills any pathogens." On top of the CDC investigation, the August Egg Company added that its internal food safety team is also "conducting its own stringent review" to identify ways to prevent such outbreaks from happening again. "We are committed to addressing this matter fully and to implementing all necessary corrective actions to ensure this does not happen again," the August Egg Company said. Customers are now being encouraged to return their eggs for a full refund or throw them away. The CDC said consumers should not eat the eggs, should wash surfaces they may have touched and should contact a healthcare provider if they experience symptoms such as diarrhea, high fever and dehydration. Per the FDA, the August Egg Company is currently not selling fresh eggs and has been "diverting eggs to an egg-breaking plant for over 30 days" to kill potential foodborne pathogens. Read the original article on People
Yahoo
an hour ago
- Yahoo
Viatris (VTRS) Faces Securities Fraud Class Action Over FDA Inspection Fallout
On May 31, 2025, Viatris Inc. (NASDAQ:VTRS) became the subject of a securities fraud class action lawsuit filed in the U.S. District Court for the Western District of Pennsylvania. The suit alleges that between August 8, 2024, and February 26, 2025, the company and certain executives made materially false or misleading statements regarding the operational status of its Indore, India manufacturing facility. Ralf Kleemann/ The complaint centers on Viatris' public assurances that its facilities were in "good operating condition" and committed to "the highest quality manufacturing standards." However, following a failed inspection, the U.S. Food and Drug Administration issued a Warning Letter and Import Alert in December 2024 that affected 11 products, including the cancer drug Lenalidomide. On February 27, 2025, Viatris (NASDAQ:VTRS) disclosed that the inspection issues would negatively impact 2025 revenue by roughly $500 million and earnings from operations by about $385 million. This revelation led to a 15% drop in Viatris' stock price, from $11.24 to $9.53 per share. Investors who purchased Viatris securities during the specified period have until June 3, 2025, to seek appointment as lead plaintiff in the lawsuit. While we acknowledge the potential of VTRS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
